Peptide drug delivery: Colonic and rectal absorption

被引:44
作者
Mackay, M
Phillips, J
Hastewell, J
机构
[1] Ciba Pharmaceut, CNS Res, CH-4002 Basel, Switzerland
[2] Ciba Pharmaceut, Drug Discovery, Horsham RH12 4BT, W Sussex, England
[3] Accel Partners, Embarcadero Ctr, San Francisco, CA 94111 USA
关键词
drug absorption; drug delivery; therapeutic peptides and proteins;
D O I
10.1016/S0169-409X(97)00076-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To date, a limited number of peptides and proteins have been used therapeutically. However, this number is growing rapidly. Some have been synthesised chemically or extracted from tissue and have been used in the clinic for decades. Recently, advances in cell and molecular biology have led to a much greater perception of the therapeutic value of many other peptides and proteins. Recombinant DNA technology has enabled high level expression and the biotechnology industry has made available large scale production for clinical use. In order to ensure that maximal use is made of this class of drug, scientists will need to devise patient compliant formulations. Clearly, these formulations will have to be safe and pharmacologically relevant. In addition, the route of administration will have to be acceptable to the patient given any particular indication. Almost all therapeutic peptides and proteins are administered by injection. It has been recognised that specific regions of the gastrointestinal tract may offer potential in terms of macromolecular absorption. This paper will address the attractiveness of the colon and rectum as routes of administration for peptide and protein drugs. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:253 / 273
页数:21
相关论文
共 152 条
[1]  
ALLEN A, 1982, COLON STRUCTURE FUNC, P45
[2]   COLONIC ABSORPTION OF HUMAN CALCITONIN IN MAN [J].
ANTONIN, KH ;
SAANO, V ;
BIECK, P ;
HASTEWELL, J ;
FOX, R ;
LOWE, P ;
MACKAY, M .
CLINICAL SCIENCE, 1992, 83 (05) :627-631
[3]  
ANTONIN KH, UNPUB INT J PHARM
[4]  
ATCHISON JA, 1989, J PHARMACOL EXP THER, V248, P567
[5]  
AUGERON C, 1986, ION GRADIENT COUPLED, P363
[6]  
AUNGST BJ, 1988, J PHARMACOL EXP THER, V244, P23
[7]   CALCITONIN - PHYSIOLOGY AND PATHO-PHYSIOLOGY [J].
AUSTIN, LA ;
HEATH, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (05) :269-278
[8]   PATHOLOGICAL INFLUENCES ON COLONIC MOTILITY - IMPLICATIONS FOR DRUG DELIVERY [J].
BARROW, L ;
SPILLER, RC ;
WILSON, CG .
ADVANCED DRUG DELIVERY REVIEWS, 1991, 7 (01) :201-218
[9]   INTRACOLONIC BIOAVAILABILITY OF HUMAN CALCITONIN IN MAN [J].
BEGLINGER, C ;
BORN, W ;
MUFF, R ;
DREWE, J ;
DREYFUSS, JL ;
BOCK, A ;
MACKAY, M ;
FISCHER, JA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (05) :527-531
[10]  
BINNS JS, 1994, P 21 INT S CONTR REL, P260